- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00157703
G207 Followed by Radiation Therapy in Malignant Glioma
A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
This study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used, i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the dose will be reduced for the following patients. The purpose of the dose de-escalation phase is to find the best safe dose of G207.
In the first stage of the study, treatment with G207 will be followed by focal radiation therapy on the following day, and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day.
All patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207 administration at which time clinical assessments will be performed, and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-3410
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy
- Failed external beam radiotherapy > 5,000 CGy at least 4 weeks prior to enrollment
- Residual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter as determined by magnetic resonance imaging (MRI)
Normal hematological, renal and liver function
- Absolute neutrophil count > 1500/mm3
- Platelets > 100,000/mm3
- Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.3 x control
- Creatinine < 1.7 mg/dl
- Total bilirubin < 1.5 mg/dl
- Transaminases < 4 times above the upper limits of the institutional norm
- Karnofsky Performance Status score ≥ 70
- Age > 19 years-old
- Capable of giving informed consent
- Must be willing to practice an effective barrier method of birth control for 2 months post G207 inoculation, whether male or female
- Females of childbearing potential: negative pregnancy test within 24 hours prior to G207 administration
Exclusion Criteria:
- Surgical resection within 4 weeks of enrolment
- Acute infection, granulocytopenia or medical condition precluding surgery
- Pregnant or lactating females
- History of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
- Tumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment or tumor involving both hemispheres or with subependymal/cerebral spinal fluid (CSF) dissemination
- Tumor position that could, in the Investigator's opinion, pose the risk of penetration of the cerebral ventricular system during inoculation with the study drug (Note: If penetration of the ventricular system is suspected or confirmed, G207 administration must be aborted.)
- Tumor locations that would expose the patient to unacceptable risk with radiation therapy
- Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpesvirus protocol)
- Prior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment
- Required steroid increase within 2 weeks prior to injection
- HIV seropositive
- Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir)
- Active oral or genital herpes lesion
- Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc.
- Radiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: from 1st dose to end of study visit
|
from 1st dose to end of study visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radiographic response
Time Frame: Withdrawal or death of last patient
|
Withdrawal or death of last patient
|
Performance scale
Time Frame: Last patient out
|
Last patient out
|
Overall survival
Time Frame: Withdrawal or death of last patient
|
Withdrawal or death of last patient
|
Immune response
Time Frame: Last patient out
|
Last patient out
|
Presence of G207 in blood and saliva
Time Frame: Last patient out
|
Last patient out
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Axel Mescheder, M.D., Medigene AG
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT2001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Annick DesjardinsAmgenTerminated
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
CellabMEDRecruitingRecurrent Malignant GliomaKorea, Republic of
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
-
Angiochem IncCompletedRecurrent or Progressive Malignant GliomaUnited States
Clinical Trials on G207
-
Gregory K. Friedman, MDCannonball Kids' Cancer Foundation; Treovir, IncActive, not recruitingBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Neoplasms, Glandular and Epithelial | Neoplasms, Germ Cell and Embryonal | Astrocytoma | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue | Neuroectodermal... and other conditionsUnited States
-
MediGeneCompletedGlioma | Glioblastoma | Astrocytoma
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Treovir, LLC; American Lebanese Syrian Associated...Not yet recruitingNeoplasms | Malignant Glioma of Brain | Glioblastoma Multiforme | High Grade Glioma | Giant Cell Glioblastoma | High-grade Glioma | Anaplastic Astrocytoma of Brain | Anaplastic GliomaUnited States
-
Gregory K. Friedman, MDMemorial Sloan Kettering Cancer Center; United States Department of Defense; Food... and other collaboratorsCompletedGlioblastoma | Malignant Glioma | PNET | Anaplastic Astrocytoma | Embryonal Tumor | Supratentorial Neoplasms, Malignant | Cerebral Primitive Neuroectodermal TumorUnited States